Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with proprietary platform developed at its laboratory facility in France. Through its wholly owned subsidiary TFChem S.A.R.L., the Company specializes in stabilizing carbohydrate molecules. The principal activities of the Company include development of cosmetic and pharmaceutical active ingredients. TFChem develops and... see more

TSXV:SBM - Post Discussion

Sirona Biochem Corp > The prc PARTNERS interview
View:
Post by forhandlaren on Jun 14, 2022 2:58pm

The prc PARTNERS interview

prc PARTNERS is a shareholder as everyone else? Or maybe not!

I think they were given information pre-deal based on:
- the interview is very polished - I like it, but very hard to accomplish in one day
- getting hold of three key management resources during the ongoing conference?
- the reference to share price close Friday June 10th on investment highlights

That raises the question of they bought shares based on in-the-know pre-deal?!

It also suggest that the close relationship indicates that the numbers published by prc PARTNERS pre- and post-deal are related to the real world. Could of course be debated.Was it $20M upfront?


Nevertheless, there are interesting breadcrumbs:
- AbbVie seems to already have started the product development which is very positive of course
- animal health deal expected to be closed this autumn
- upfront is invested in accelerated development
- $40M royalty equals about 1.86 CAD per share at P/E 10 and 275M shares - does prc PARTNERS speculate or are they in-the-know? Doesn't really matter as the numbers seems realistic anyway.


Sirona Biochem states on Twitter that "There are many more news to come in the next days" - does it refer to the post-deal interview or something else? I would be very surprised if there's more to bring to the market this week given the prc PARTNERS interview that covers a lot.
Comment by Transperance on Jun 15, 2022 1:44am
I can´t see where you found the 20M upfront figure, but the level is reasonable, I guess. It is evident that the company will expand the R&D activities in France, so the upfront certainly needs to be a fair amount.  When it comes to the royalty figure, I agree that 5% flat is an adequate estimate to use. I have found a study that points in that direction: https ...more  
Comment by forhandlaren on Jun 15, 2022 2:46am
prc PARTNERS launched a new web site more or less at the same time as Sirona launched theirs. Old posts were removed in the process. Thanks for the article, good read. Seems like an upfront between 2M and 20M is reasonable (USD, multiply with 1.28 for CAD). Since milestones are involved, the upfront might be in the lower span.
Comment by noclue80 on Jun 15, 2022 3:35am
TFC-1067 0,4% study release? finally?!
Comment by jimmyhorizon on Jun 15, 2022 7:10am
no the question is not whether someone bought in the know before the deal, but sold in the know after the hype.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities